Market access in Mexico refers to the full chain of activities required to make a registered medical device or pharmaceutical commercially available to end users from structuring a distribution partnership or subsidiary, to listing products in public procurement catalogs (IMSS, ISSSTE, state-level tenders), to negotiating formulary inclusion in private hospital networks.
Unlike regulatory approval, which is binary (approved or not), market access is a continuous commercial process that determines where, how, and at what price your product reaches patients. In Mexico, the distribution landscape is dominated by a small number of large national distributors alongside hundreds of regional and specialized players, making partner selection one of the highest-leverage decisions in any go-to-market plan.
Most international healthcare companies invest heavily in COFEPRIS registration and market research then hand distribution to the first local partner who shows interest. This is the single most common and most expensive mistake in Mexico market entry. The wrong distribution partner can lock your product into unfavorable pricing, limit your reach to a single channel, and in worst-case scenarios, hold your COFEPRIS registration hostage.
Mexico’s distribution landscape is structurally different from the US or Europe. Public procurement (IMSS, ISSSTE, state tenders) accounts for roughly 55% of medical device volume, but requires specialized tender expertise, bonding capacity, and government relationships that most international companies cannot develop on their own. The private channel (1,200+ hospitals, group purchasing organizations) offers higher margins but demands clinical evidence packages, KOL relationships, and a different sales motion entirely.
The strategic question is not simply “who will distribute my product?” but rather: what is the right structure? Options range from appointing a single exclusive national distributor, to a hybrid model with separate public and private partners, to establishing your own Mexican entity with a direct sales force. Each carries distinct trade-offs in control, capital, speed, and risk — and the right answer depends on your product category, volume ambitions, and appetite for operational complexity.
This hub brings together our complete library of Mexico distribution and market access content — from distribution model comparisons and partner evaluation frameworks to pricing strategy and the own-entity decision. Whether you are selecting your first Mexican distribution partner or restructuring an underperforming channel, you will find specific, actionable guidance based on our experience launching 350+ products across medical devices, diagnostics, and pharmaceuticals in Mexico.
.jpg)
